You're receiving this email because you're subscribed to Cannabis Daily from Benzinga. To manage your subscription, click the link at the bottom of this email.

Happy Monday Cannabis Investors, and welcome to the cannabis newsletter from Benzinga. The goal of this newsletter is to keep you up-to-date on the fast-moving world of cannabis investing. How? By providing super high-quality content directly to your inbox everyday.

For example, today we're diving into why the FDA has rejected MDMA for PTSD treatment.

In addition to this top story, we’ve also got a daily mix news, analysis, regulatory updates, and much more.

If there are any other ways we can make your life easier, please reply to this email to let us know. Also, if you don’t think this will be a valuable daily resource, you can scroll to the bottom to unsubscribe.

TOP STORY

Public Backs Athletes

Briefly: Public opinion is shifting as 42% of people now believe that recreational drug use should not disqualify athletes from participating in the Olympics, according to a recent survey. This growing support reflects changing attitudes towards drug policies in sports and raises important questions about fairness, performance, and the role of recreational substances.

What does this mean for the future of Olympic regulations and the athletes affected by these policies? Read more to find out.

PRESENTED BY CANNABIS CAPITAL CONFERENCE

We have an exciting announcement for our upcoming Benzinga Cannabis Capital Conference on October 8th and 9th in Chicago! The entertainer and founder of Oregon-based Belushi's Farm, Jim Belushi will be joining us as Keynote Speaker.

Get your tickets now!

ZINGERS

NYPD Bust: Burglary Call Leads NYPD To $5M Illegal Cannabis Operation Bust In Queens

Cannabis Stocks: Simply Better's Q2 Gross Profit Increases 83% YoY, Revenue Down 17% As CBD Segment Dips

Recreational Cannabis: Heavy Cannabis Use Linked To Higher Head And Neck Cancer Risk, New Study Finds

Cannabis Jobs: Cannabis Workers Will Unionize In Oregon If Ballot Measure Is Approved In November Elections

ONE MORE FOR THE ROAD

FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy

Briefly: In a surprising move, the FDA has rejected MDMA for PTSD treatment, citing the need for more research on psychedelic therapy. Despite promising clinical trial results and growing support from the medical community, the decision underscores the regulatory hurdles faced by psychedelic treatments. What does this mean for the future of MDMA and other psychedelic therapies in mental health care?

Click to delve into the FDA's decision, the implications for PTSD treatment, and the next steps in psychedelic research.

PRESENTED BY CANNABIS CAPITAL CONFERENCE

Join us on October 8th and 9th in Chicago for the world's largest gathering of cannabis investors - happening just ONE month before the Presidential election.

Get your tickets now on bzcannabis.com – Prices will increase very soon!

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Ring The Bell: Created for market enthusiasts by market enthusiasts, this twice-daily newsletter delivers top stories, fast movers, and hot trade ideas straight to your inbox. Subscribe here.

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Real Estate Weekly: Where we highlight the movers and the losers, the upgrades and the downgrades, the top stories and opportunities in the trillion dollar REIT and real asset industry. Subscribe here.

Mining Weekly: Get an insider's edge with news, analysis, and commentary on what’s shaping the mining and commodities industry that powers the global economy. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.